Peptone

Peptone is a biotechnology therapeutics company that uses AI and an experimental physics product engine to design first-in-class small molecules targeting intrinsically disordered proteins (IDPs) — the 6,200 human proteins that AlphaFold 3 cannot model. The company's bespoke hydrogen-deuterium exchange mass spectrometry technology reveals binding pockets invisible to conventional structural biology, while its GPU-based supercomputing engine enables small molecule design in weeks rather than years. Peptone's pipeline is focused on oncology indications where IDPs play a central role. Backed by F-Prime Capital, Bessemer Venture Partners, Hoxton Ventures, Novartis, and Walden Catalyst, Peptone operates labs in London and Switzerland.